Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.750
-0.060 (-3.31%)
Dec 17, 2025, 3:40 PM EST - Market open
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 213 employees as of December 31, 2024. The number of employees increased by 5 or 2.40% compared to the previous year.
Employees
213
Change (1Y)
5
Growth (1Y)
2.40%
Revenue / Employee
$290,329
Profits / Employee
$25,324
Market Cap
140.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 213 | 5 | 2.40% |
| Dec 31, 2023 | 208 | 11 | 5.58% |
| Dec 31, 2022 | 197 | -9 | -4.37% |
| Dec 31, 2021 | 206 | -1 | -0.48% |
| Dec 31, 2020 | 207 | 11 | 5.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLX News
- 8 hours ago - Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - PRNewsWire
- 4 weeks ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - PRNewsWire
- 5 weeks ago - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - PRNewsWire
- 6 weeks ago - PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 6 weeks ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - GlobeNewsWire
- 2 months ago - Why Is Protalix BioTherapeutics Stock Falling On Friday? - Benzinga
- 2 months ago - Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire